Krugliak M - Search Results

1

Computational and experimental analysis of drug binding to the Influenza M2 channel.

Alhadeff R, Assa D, Astrahan P, Krugliak M, Arkin IT. Alhadeff R, et al. Among authors: krugliak m. Biochim Biophys Acta. 2014 Apr;1838(4):1068-73. doi: 10.1016/j.bbamem.2013.07.033. Epub 2013 Sep 7. Biochim Biophys Acta. 2014. PMID: 24016551 Free article.

2

Quantitative analysis of influenza M2 channel blockers.

Astrahan P, Flitman-Tene R, Bennett ER, Krugliak M, Gilon C, Arkin IT. Astrahan P, et al. Among authors: krugliak m. Biochim Biophys Acta. 2011 Jan;1808(1):394-8. doi: 10.1016/j.bbamem.2010.08.021. Epub 2010 Sep 8. Biochim Biophys Acta. 2011. PMID: 20831860 Free article.

3

How do aminoadamantanes block the influenza M2 channel, and how does resistance develop?

Leonov H, Astrahan P, Krugliak M, Arkin IT. Leonov H, et al. Among authors: krugliak m. J Am Chem Soc. 2011 Jun 29;133(25):9903-11. doi: 10.1021/ja202288m. Epub 2011 May 16. J Am Chem Soc. 2011. PMID: 21534619

4

Bacteria-based analysis of HIV-1 Vpu channel activity.

Taube R, Alhadeff R, Assa D, Krugliak M, Arkin IT. Taube R, et al. Among authors: krugliak m. PLoS One. 2014 Oct 1;9(10):e105387. doi: 10.1371/journal.pone.0105387. eCollection 2014. PLoS One. 2014. PMID: 25272035 Free PMC article.

5

Mapping the Resistance Potential of Influenza's H⁺ Channel against an Antiviral Blocker.

Assa D, Alhadeff R, Krugliak M, Arkin IT. Assa D, et al. Among authors: krugliak m. J Mol Biol. 2016 Oct 9;428(20):4209-4217. doi: 10.1016/j.jmb.2016.08.007. Epub 2016 Aug 11. J Mol Biol. 2016. PMID: 27524470

6

Blockers of the SARS-CoV-2 3a Channel Identified by Targeted Drug Repurposing.

Tomar PPS, Krugliak M, Arkin IT. Tomar PPS, et al. Among authors: krugliak m. Viruses. 2021 Mar 23;13(3):532. doi: 10.3390/v13030532. Viruses. 2021. PMID: 33807095 Free PMC article.

7

Promiscuous binding in a selective protein: the bacterial Na+/H+ antiporter.

Alhadeff R, Ganoth A, Krugliak M, Arkin IT. Alhadeff R, et al. Among authors: krugliak m. PLoS One. 2011;6(10):e25182. doi: 10.1371/journal.pone.0025182. Epub 2011 Oct 12. PLoS One. 2011. PMID: 22022382 Free PMC article.

8

Potential Viroporin Candidates From Pathogenic Viruses Using Bacteria-Based Bioassays.

Tomar PPS, Oren R, Krugliak M, Arkin IT. Tomar PPS, et al. Among authors: krugliak m. Viruses. 2019 Jul 9;11(7):632. doi: 10.3390/v11070632. Viruses. 2019. PMID: 31324045 Free PMC article.

9

Identification of SARS-CoV-2 E Channel Blockers from a Repurposed Drug Library.

Tomar PPS, Krugliak M, Arkin IT. Tomar PPS, et al. Among authors: krugliak m. Pharmaceuticals (Basel). 2021 Jun 23;14(7):604. doi: 10.3390/ph14070604. Pharmaceuticals (Basel). 2021. PMID: 34201587 Free PMC article.

10

Zika M-A Potential Viroporin: Mutational Study and Drug Repurposing.

Tomar PPS, Krugliak M, Singh A, Arkin IT. Tomar PPS, et al. Among authors: krugliak m. Biomedicines. 2022 Mar 10;10(3):641. doi: 10.3390/biomedicines10030641. Biomedicines. 2022. PMID: 35327443 Free PMC article.

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Article Language

Species

Sex

Age

Other

51 results

Search Page

Filters